Imaging characteristics of 4th ventricle subependymoma

Ali S. Haider1 · Tarek Y. El Ahmadieh2 · Maryam Haider3 · Kimmo J. Hatanpaa4 · Marco C. Pinho5 · Bruce E. Mickey2 · Raymond Sawaya6 · Gregory N. Fuller7 · Donald F. Schomer3 · Maria Gule-Monroe3

Received: 24 December 2021 / Accepted: 4 April 2022 / Published online: 15 April 2022
© The Author(s) 2022

Abstract
Purpose Subependymomas located within the 4th ventricle are rare, and the literature describing imaging characteristics is sparse. Here, we describe the clinical and radiological characteristics of 29 patients with 4th ventricle subependymoma.

Methods This is a retrospective multi-center study performed after Institutional Review Board (IRB) approval. Patients diagnosed with suspected 4th ventricle subependymoma were identified. A review of clinical, radiology, and pathology reports along with magnetic resonance imaging (MRI) images was performed.

Results Twenty-nine patients, including 6 females, were identified. Eighteen patients underwent surgery with histopathological confirmation of subependymoma. The median age at diagnosis was 52 years. Median tumor volume for the operative cohort was 9.87 cm³, while for the non-operative cohort, it was 0.96 cm³. Thirteen patients in the operative group exhibited symptoms at diagnosis. For the total cohort, the majority of subependymomas (n = 22) were isointense on T1, hyperintense (n = 22) on T2, and enhanced (n = 24). All tumors were located just below the body of the 4th ventricle, terminating near the level of the obex. Fourteen cases demonstrated extension of tumor into foramen of Magendie or Luschka.

Conclusion To the best of our knowledge, this is the largest collection of 4th ventricular subependymomas with imaging findings reported to date. All patients in this cohort had tumors originating between the bottom of the body of the 4th ventricle and the obex. This uniform and specific site of origin aids with imaging diagnosis and may infer possible theories of origin.

Keywords Subependymoma · Fourth ventricle · Neuroimaging · Rare tumors

Introduction

Subependymoma is a rare central nervous system neoplasm that is classified as a grade I tumor by the World Health Organization (WHO) [1–4]. It is of subependymal origin and represents approximately 0.2–0.7% of all intracranial tumors [2, 5–7]. The first pathological description of subependymoma was reported in 1945, with few clinical studies reported since then [1, 8, 9]. These lesions are typically discovered incidentally and are usually asymptomatic [10].

Subependymomas are most commonly found in the fourth and lateral ventricles; however, a number of studies have reported lesions located in the spinal cord [3, 11–13]. Histologically, they appear as clusters of isomorphic nuclei embedded in a dense glial fibrillary matrix. Symptomatic lesions most frequently present with hydrocephalus and headache. Surgery is considered the primary treatment option for symptomatic cases [9, 14, 15]. There is a paucity in the literature regarding the imaging characteristics of these rare tumors. Here, we describe the clinical and
radiological characteristics of 29 patients with fourth ventricle subependymoma as observed in two tertiary care academic medical centers.

**Methods**

**Study design**

This retrospective case series was performed after Institutional Review Board (IRB) approval at two participating institutions. Patients with intracranial subependymoma were identified via a database search at the University of Texas M.D. Anderson Cancer Center and the University of Texas Southwestern Medical Center. Patients 18 years of age or older diagnosed with fourth ventricle subependymoma via magnetic resonance imaging (MRI) or histopathology from 1993 to 2019 were included in the study. Exclusion criteria consisted of patients younger than 18 years of age, subependymoma located outside the fourth ventricle, or absence of MRI images. A retrospective review of clinical, radiological (MRI), and pathological data was performed. MRI appearance was used to make the diagnosis of subependymoma in cases where surgical pathology was unavailable. All MRI images were reviewed by 3 fellowship-trained, board certified neuroradiologists with greater than 4 years of experience.

**Study variables**

Patient demographic and imaging variables such as age, gender, date of initial MRI, date of last MRI, date of surgery, and symptoms at diagnosis were collected. Specific imaging variables for each patient collected included tumor location, tumor size, degree of enhancement, intensity of enhancement, appearance on T1, T2, FLAIR, DWI, GRE, and any change in imaging. The degree of enhancement was further characterized as non-enhancing, partially enhancing, and completely enhancing. The intensity of enhancement was further characterized based on the highest degree of enhancement into 3 categories: avid, moderate, and mild. Avid enhancement was defined as enhancement intensity similar to homogeneous dural venous sinus enhancement without flow artifacts. Moderate enhancement was defined as enhancement intensity similar to the degrees of enhancement of the choroid plexus. Mild enhancement was defined as enhancement intensity less than that of the choroid plexus. The change in imaging was defined as a minimum 25% increase in baseline tumor size for patients managed conservatively, while for patients treated via surgery, the change in imaging was defined as tumor recurrence.

**Statistical analysis**

Tumor volume was calculated as [Anteroposterior × Transverse × Cranio-caudal]. Analysis for descriptive statistics was performed using the statistical software SPSS V.24 (IBM Corp., Armonk, New York).

**Results**

**Demographics and clinical features**

Twenty-nine patients, including 6 females, were included. Eighteen patients (62%) underwent surgery with histopathological confirmation of subependymoma. The median age at diagnosis was 52 years. The median tumor volume for the operative cohort was 9.87 cm³, while for the non-operative cohort, it was 0.96 cm³. For the total cohort, the cranio-caudal diameter range was (min) 0.56 cm–(max) 5.60 cm and median was 2.00 cm. Thirteen patients (45%) were symptomatic on presentation, all of whom subsequently underwent surgical resection. The most common presenting symptoms were headache (n = 6) and dizziness (n = 5). The median length of follow-up in the operative cohort was 25.90 months, and no tumor recurrence was noted after surgical resection. In the non-operative cohort, the median length of follow-up was 65.70 months and all cases demonstrated no change in baseline tumor size (Table 1).

**MRI characteristics**

For the total cohort, the majority of subependymomas (n = 22; 76%) were isointense on T1-weighted sequences and hyperintense (n = 22; 76%) on T2-weighted sequences. All subependymomas with available FLAIR imaging (n = 28; 97%) demonstrated FLAIR hyperintensity. Out of the 27 patients that had a DWI sequence available for review, only one subependymoma demonstrated restricted diffusion on diffusion weighted imaging. Susceptibility artifact of the tumor was present in 15 out of 20 patients with T2* imaging available for review. The susceptibility artifact correlated with coarse calcification on non-contrast CT of the head in 2 patients that had a CT available for comparison.

The majority of subependymomas were enhanced on post-contrast T1-weighted sequence (n = 24; 83%). However, enhancement was only partial, with no tumors found to be completely enhancing. The intensity of enhancement ranged from mild (n = 6; 21%) to moderate (n = 16; 55%), along with one tumor demonstrating avid enhancement and one tumor considered too heterogeneous in intensity to further classify in either category (Fig. 1A–D). Within the 4th
ventricle, all tumors \((n = 29; 100\%)\) were noted to be centered below the body of the 4th ventricle and terminating near the level of the obex. Three patients had obstructive hydrocephalus at the time of presentation. Fourteen cases (48%), 13 of which were in the operative cohort, demonstrated tumor extension into the foramen of Magendie or Luschka (Fig. 2). Median tumor volume for cases with foramen extension was 10.95 cm\(^3\), while for the cases without foramen extension, it was 1.13 cm\(^3\).

### Discussion

In this study, we report the largest imaging experience to date on 4th ventricular subependymoma. The majority of patients in this study were confirmed histopathologically as subependymomas. Also included were adult patients with tumors of the 4th ventricle that exhibited imaging stability over time in keeping with low-grade neoplasm, thus excluding other known pathologic entities of the 4th ventricle known to be progressive lesions such as ependymoma or medulloblastoma [21–25]. This strategy also excluded 4th ventricular tumors that although low-grade are known to be symptomatic requiring surgery such as choroid plexus papillomas or pilocytic astrocytoma and known to have an aggressive course when presenting in adulthood [22–28]. Furthermore, the MR imaging characteristics appeared relatively uniform between the operative and non-operative cohort, supporting a common pathology.

Our study is the first to identify a specific site of origin for 4th ventricular subependymomas. All patients in our cohort were found to have tumors originating below the body of the 4th ventricle and above the obex. This observation in conjunction with long-term imaging stability suggests the likely diagnosis for these rare tumors. Furthermore, the presence of tumor at the foramen of Luschka or Magendie as well as

---

### Table 1 Patient demographics and radiological characteristics

| Patient demographics | Total cohort | Operative | Non-operative |
|----------------------|-------------|-----------|---------------|
| Gender               | 23 M; 6 F   | 14/18 cases | 9/11 cases    |
| Age (median)         | 52 years    | 2/18 cases | 1/11 cases    |
| T1 \((n = 29)\)      | Isointense 22/29 cases | 14/18 cases | 8/11 cases    |
| Hyperintense         | 1/29 cases  | 0/18 cases | 1/11 cases    |
| Hypointense          | 4/29 cases  | 2/18 cases | 2/11 cases    |
| Mixed (Iso + Hypo)   | 2/29 cases  | 2/18 cases | 0/11 cases    |
| T2 \((n = 29)\)      | Isointense 5/29 cases | 2/18 cases | 3/11 cases    |
| Hyperintense         | 22/29 cases | 15/18 cases | 7/11 cases    |
| Hypointense          | 1/29 cases  | 0/18 cases | 1/11 cases    |
| FLAIR \((n = 28)\)   | Hyperintense 28/28 cases | 17/17 cases | 11/11 cases |
| GRE/T2* \((n = 20)\) | Susceptibility present 15/20 cases | 9/10 cases | 6/10 cases    |
| DWI \((n = 27)\)     | Restricted diffusion 1/27 cases | 1/17 cases | 0/10 cases    |
| Enhancement \((n = 29)\) | Present 24/29 cases | 15/18 cases | 9/11 cases    |
| Location             | Centered below body of 4th ventricle 29/29 cases | 18/18 cases | 11/11 cases |
| Extension into Foramen of Magendie or Luschka | 14/29 cases | 13/18 cases | 1/11 cases    |

\(n=\) number of patients that had this imaging sequence done
larger tumor size was observed to be linked with clinical symptoms requiring surgical resection. This is in contrast to the patients that were placed on imaging surveillance where no patients exhibited symptoms, only one patient had tumor at the foramen of Luschka, and tumors were noted to be smaller in size compared to the operative cohort.

As noted in the literature, intracranial subependymomas are most commonly found in the fourth and lateral ventricles [10, 16–18]. Within the fourth ventricle, we observed all of the subependymomas in our study to be centered below the body of the fourth ventricle and terminating at the level of the obex. We postulate that this neuroanatomical finding may have a developmental relationship with the area postrema, a circumventricular paired structure in the medulla oblongata of the brainstem [19]. The area postrema is located at the floor of the fourth ventricle, highly vascular, and lined by glial cells. The cell of origin for subependymomas is thought to originate from neural stem cells. Bennett et al. have suggested that circumventricular organs such as the area postrema may be a novel source of neural stem cells, raising the developmental concept of subependymomas originating in this area [20]. Obviously, this hypothesis requires further investigation.

Radiographic findings in our study revealed that fourth ventricle subependymomas are more commonly isointense on T1, hyperintense on T2, enhance, and demonstrate FLAIR hyperintensity. The presence of susceptibility artifact was seen in 75% of our patients and was found to represent coarse calcification on CT in a limited number of patients that had CT available for comparison. Though the majority of cases in our study demonstrated enhancement, it is worth noting that most of these tumors exhibited relatively mild to moderate enhancement. This is generally consistent with what has been previously described in multiple retrospective case series with regards to intracranial subependymoma [8, 10–12, 16–18, 21, 22]. It is worth noting that none of our lesions demonstrated complete enhancement, and only one demonstrated avid enhancement. This may be helpful when differentiating from lesions with characteristic complete or avid enhancement, such as papillomas, meningiomas, and hemangioblastomas [23–28].

Nearly half of the cases in our study demonstrated tumor extension outside of the fourth ventricle, either into foramen of Magendie or Luschka. Though sparingly noted in the literature, no studies have drawn any correlation between subependymoma extension outside of the fourth ventricle
and diagnosis [18]. However, we observed that the larger tumors in our study appeared to have a greater incidence of extension outside of the fourth ventricle.

There was an appreciable difference in tumor size between the operative and non-operative cohorts in our series, with the operative tumor cohort being consistently larger in size than the non-operative cohort. All symptomatic lesions in our study underwent surgical resection. The most common symptoms noted in our study included headache and dizziness, which are consistent with the literature [10, 14, 22, 29]. Obstructive hydrocephalus was also observed in three of our patients before surgery, which was noted in the literature to be a particular sequelae of fourth ventricle subependymoma [10, 17, 18]. None of the cases in our study experienced tumor recurrence, consistent with the literature regarding the clinical management and cellular growth of intracranial subependymoma [8, 9, 12–15, 30].

Our study is a retrospective case series pooling data from two large tertiary academic medical centers. It has several limitations, including inherent bias due to the retrospective and observational nature of the study. A possible geographic bias regarding patient demographics can also limit our study due to both participating institutions being in the same region, while patient insurance status can also possibly bias the patient cohort that was available for our study. Our small sample size may be biased toward larger or more symptomatic lesions, since asymptomatic lesions are less likely to present and undergo imaging. Also, our cohort consists of only 18 patients with a histologically confirmed diagnosis. Our length of follow-up is relatively short; however, it is understood that these are benign tumors. Furthermore, a larger study would be difficult to perform for such rare and indolent tumors.

Conclusions

To the best of our knowledge, this study is the largest imaging experience of 4th ventricular subependymomas reported in the literature to date. These tumors are noted to have characteristic imaging features and a propensity to be located below the body of the fourth ventricle, terminating at the level of the obex. Larger, prospective multi-center studies are required to further determine the clinical and imaging characteristics of these tumors.

Acknowledgements This study was made possible by the Silverman Subependymoma Fund. We also thank Mr. Jordan Pietz for his medical illustration assistance.
Funding Silverman Subependymoma Fund.

Data availability The datasets generated/analyzed during this study are not publicly available due to data protection but are available from the corresponding author upon reasonable request.

Code availability N/A.

Declarations

Conflict of interest We declare that we have no conflict of interest.

Ethics approval This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Human Investigation Committee (IRB) of MD Anderson Cancer Center and The University of Texas Southwestern Medical Center approved this study.

Informed consent Per the ethics approval statement listed above, our study was allowed to proceed after Institutional Review Board (IRB) approval without specific patient informed consent due to our study being a retrospective, observational study only.

Consent for publication N/A

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Scheinker I (1945) Subependymoma: a newly recognized tumor of subependymal derivation. J Neurosurg 2:232–240
2. Louis DN et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820
3. Scheithauer BW (1978) Symptomatic subependymoma. Report of 21 cases with review of the literature. J Neurosurg 49(5):689–96
4. Louis DN et al (2021) The 2021 WHO Classification of Tumors of the central nervous system: a summary. Neuro Oncol 23(8):1231–1251
5. Moss TH (1984) Observations on the nature of subependymoma: an electron microscopic study. Neuropathol Appl Neurobiol 10(1):63–75
6. Boykin FC et al (1954) Subependymal glomerate astrocytomas. J Neuropathol Exp Neurol 13(1):30–49
7. Godwin JT (1959) Subependymal glomerate astrocytoma; report of two cases. J Neurosurg 16(4):385–389
8. Bi Z et al (2015) Clinical, radiological, and pathological features in 43 cases of intracranial subependymoma. J Neurosurg 122(1):49–60
9. Rushing EJ et al (2007) Subependymoma revisited: clinicopathological evaluation of 83 cases. J Neurolonc 85(3):297–305
10. Jain A et al (2012) Subependymoma: clinical features and surgical outcomes. Neurol Res 34(7):677–684
11. Chiocchi MV, Smirniotopoulos JG, Jones RV (1995) Intracranial subependymomas: CT and MR imaging features in 24 cases. AJR Am J Roentgenol 165(5):1245–1250
12. D’Amico RS et al (2017) Subependymomas are low-grade heterogeneous glial neoplasms defined by subventricular zone lineage markers. World Neurosurg 107:451–463
13. Lombardi D et al (1991) Symptomatic subependymoma: a clinicopathological and flow cytometric study. J Neurosurg 75(4):583–588
14. Nguyen HS et al (2017) Intracranial subependymoma: a SEER analysis 2004–2013. World Neurosurg 101:599–605
15. Regel BT et al (2006) Subependymomas: an analysis of clinical and imaging features. Neurosurgery 58(5):881–90
16. Hoeftel C et al (1995) MR manifestations of subependymomas. AJNR Am J Neuroradiol 16(10):2121–2129
17. Jooa R et al (1985) Subependymomas of the fourth ventricle. Surgical treatment in 12 cases. J Neurosurg 62(4):508–12
18. Kammerer S et al (2018) Subependymomas - characteristics of a “Leave me Alone” Lesion. Rofo 190(10):955–966
19. Mirza M, Das JM (2020) Neuroanatomy, Area Postrema. StatPearls, Treasure Island
20. Bennett L et al (2009) Circumventricular organs: a novel site of neural stem cells in the adult brain. Mol Cell Neurosci 41(3):337–347
21. Ernestus RI, Schroder R (1993) Clinical aspects and pathology of intracranial subependymomas–18 personal cases and review of the literature. Neurochirurgia (Stuttg) 36(6):194–202
22. Fujisawa H, Hasegawa M, Ueno M (2010) Clinical features and management of five patients with supratentorial subependymoma. J Clin Neurosci 17(2):201–204
23. Safaee M et al (2013) Choroid plexus papillomas: advances in molecular biology and understanding of tumorigenesis. Neuro Oncol 15(3):255–267
24. Zhang TJ et al (2011) MRI findings of choroid plexus tumors in the cerebellum. Clin Imaging 35(1):64–67
25. Elster AD et al (1989) Meningiomas: MR and histopathologic features. Radiology 170(3 Pt 1):857–862
26. Tamrazi B, Shirouhji MS, Liu CS (2016) Advanced Imaging of Intracranial Meningiomas. Neurosurg Clin N Am 27(2):137–143
27. Glasker S, Van Velthoven V (2005) Risk of hemorrhage in hemangioblastomas of the central nervous system. Neurosurgery 57(1):71–6
28. Slater A, Moore NR, Huson SM (2003) The natural history of cerebellar hemangioblastomas in von Hippel-Lindau disease. AJNR Am J Neuroradiol 24(8):1570–1574
29. Varma A et al (2018) Surgical management and long-term outcome of intracranial subependymoma. Acta Neurochir (Wien) 160(9):1793–1799
30. Kong LY et al (2014) Therapeutic targets in subependymoma. J Neuroimmunol 277(1–2):168–175

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.